GSK plc has received regulatory approval from China’s National Medical Products Administration (NMPA) to market Trelegy Ellipta, a once-daily inhaled combination of fluticasone furoate, umeclidinium, and vilanterol, for the treatment of adult patients with uncontrolled asthma. This decision expands Trelegy Ellipta’s label beyond its existing indication in chronic obstructive pulmonary disease (COPD), making it the […]
SonoMotion’s Break Wave lithotripsy device wins FDA clearance for non-invasive kidney stone treatment. Find out what this changes for urology practices.
NERLYNX launches in Thailand for HER2+ breast cancer. Find out how neratinib could reshape relapse prevention and treatment sequencing across Southeast Asia.
